Loading…
Merger aims to advance drug discovery for resistant cancers.
N2OFF, Inc. (NASDAQ: NITO) and MitoCareX Bio Ltd. (MitoCareX) announced on 2025-09-25 N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer.
The announcement cited 6,622 shares, $700,000, 40%, 30%, $1.6 million, $1,000,000, 25%, $194.1B, and $344.1B. Share consideration (payable in the issuer's shares): 6,622 shares.
Nexentis Technologies Inc. Common Stock has a free float of 1,389,800 shares and 2,712,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.